AMWL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
AMWL is not a good buy right now for a Beginner long-term investor with $50,000-$100,000 to deploy. The stock has momentum, but it is already overbought and the long-term fundamentals still show revenue and earnings declines. Since the user is impatient and not waiting for an ideal entry, the direct call is to hold off rather than buy now.
AMWL is in a short-term bullish trend: MACD is positive and expanding, and moving averages are aligned bullishly with SMA_5 > SMA_20 > SMA_200. However, RSI_6 at 83.953 signals a heavily overbought condition, which makes the current price a stretched entry. Price at 7.62 is below the 7.75 prior close after a strong regular-session move, and resistance sits near 7.87 while support is around 6.67. The stock-trend model also points to weakness over the next day, week, and month despite the recent rally.
["Q1 2026 revenue beat expectations at $54.9M.", "Subscription revenue and visits revenue were strong.", "Full-year 2026 adjusted EBITDA loss guidance improved to between $12M and $16M.", "Cash and investments of $179M with no debt provide balance sheet support.", "Q2 2026 revenue guide of $48M-$52M signals continued growth potential.", "Analyst price targets moved up after earnings."]
["Q1 2026 revenue was still down 17.88% YoY.", "Net income and EPS declined year over year.", "Gross margin compressed to 39.31%, down 5.30% YoY.", "The stock is technically overbought after the recent jump.", "Similar candlestick pattern analysis suggests downside over the next day, week, and month.", "No AI Stock Picker or SwingMax buy signal is present today."]
In Q1 2026, American Well reported revenue of $54.883M, which was down 17.88% year over year, so top-line growth is still negative. Net income was -$10.886M, EPS was -$0.66, and gross margin fell to 39.31%, showing that profitability remains under pressure despite operational improvement. The quarter season is Q1 2026, and the main positive is that management raised EBITDA expectations and has strong cash with no debt.
Recent analyst sentiment improved after earnings. TD Cowen raised its target to $8 from $5 and kept Hold, while Morgan Stanley raised its target to $6.50 from $6 and kept Equal Weight. Earlier in February, both Stifel and TD Cowen lowered targets and stayed Hold because revenue guidance was weak. Wall Street’s current view is mixed: pros like the revenue beat, better EBITDA outlook, and cost discipline; cons remain centered on revenue contraction, strategic restructuring, and the fact that ratings are still only Hold/Equal Weight rather than Buy.
